Latest news with #neuromodulation
Yahoo
2 days ago
- Business
- Yahoo
electroCore to Announce Second Quarter June 30, 2025 Financial Results on Wednesday, August 6, 2025
ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the close of the market on Wednesday, August 6, 2025. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Dial-In: (646) 931-3860Webinar ID: 843 8084 9004 Passcode: 049555Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company's two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance. For more information, visit Contact ECOR Investor Relations(973) 302-9253investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
4 days ago
- Business
- Globe and Mail
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Investor Contact: Mark Klausner or Mike Vallie ICR Westwicke 443-213-0501 ir@ Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 emeyers@
Yahoo
17-07-2025
- Health
- Yahoo
Saluda Medical Announces Full U.S. Launch of EVA™ Sensing Technology for Use with the Evoke® SmartLoop™ System
New Clinical Data on EVA to be Presented at ASPN 2025 Annual Conference MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the full commercial launch of EVA, its next-generation sensing technology, in the United States (U.S.). EVA received U.S. Food & Drug Administration (FDA) approval in December 2024 and is compatible with all commercially implanted Evoke® SmartLoop™ System patients. EVA, an extension of the Evoke System, objectively scans and analyzes a patient's spinal cord to deliver personalized therapy with precision beyond human capability. The Evoke SmartLoop System optimizes patient outcomes by sensing, measuring, and adjusting stimulation based on each patient's neural response biomarker, known as the evoked compound action potential (ECAP), to maintain therapy at the patient's prescribed level. "This full commercial launch represents a significant advancement in SCS therapy and delivers on the promise of objective dosing and more effective pain relief for patients," said Mike Mathias, Chief Commercial Officer at Saluda Medical. "In addition to its clinical benefits, EVA automates manual programming steps, thereby improving the patient experience. Since receiving FDA approval at the end of last year, EVA has been utilized in over 3,000 commercial patient visits through a limited market release." New clinical data to be presented at the American Society of Pain and Neuroscience (ASPN) 2025 Annual Conference, to be held July 17 – 20, 2025 in Miami, FL, will feature 11 abstracts and one oral presentation, which add to Saluda Medical's significant body of existing clinical evidence, including over 37 total publications. Among these are results from the landmark EVOKE Study, which demonstrated long-term efficacy out to 36-months. "The Evoke SmartLoop System with EVA provides objective dosing that enables more predictable and durable outcomes in SCS," said Jason Pope, MD, Founder and CEO, Evolve Restorative Center. "The data premiering at ASPN 2025 further demonstrates the compelling clinical benefits of the Evoke SmartLoop System, including increasing the diagnostic value of the trial phase and maintaining therapy response over time without loss of efficacy." About Saluda MedicalSaluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. Investor Contacts: Brian Johnston or Sam Bentzingerbrian@ sam@ View original content to download multimedia: SOURCE Saluda Medical Sign in to access your portfolio
Globe and Mail
10-07-2025
- Business
- Globe and Mail
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
Boston Scientific 's BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the WATCHMAN devices are also encouraging. The company's impressive strategic acquisitions provide a favorable opportunity for growth. Meanwhile, headwinds like currency fluctuations are concerning for its operations. In the past year, this Zacks Rank #2 (Buy) company's shares have rallied 33.6% compared with the industry and the S&P 500 composite's growth of 11.7% and 10.1%, respectively. The renowned manufacturer of medical devices and products has a market capitalization of $153.61 billion. BSX beat on earnings in each of the trailing four quarters, delivering an average surprise of 8.79%. Let us delve deeper. Upsides for BSX Stock MedSurg's Impressive Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg is gaining from strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. Within Urology, Boston Scientific continues to expand market share globally. The company's Stone management and prostheticurology franchises are growing well, led by key launches with the TENACIO pump for the AMS 700 and continued success with the expanding LithoVue portfolio. Within Neuromodulation, Boston Scientific's pain and brain businesses are gaining traction. Within deep brain stimulation, the company expects to see improved growth in 2025, backed by the recent FDA and CE Mark approvals of the Cartesia X and HX leads. WATCHMAN, a Long-Term Growth Driver: Boston Scientific's structural heart programs are fast building momentum on the back of strong performance of the WATCHMAN left atrial appendage closure device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally. The next generation WATCHMAN FLX and FLX Pro are capturing the global market. In the first quarter of 2025, WATCHMAN sales increased 24% year over year, with a strong contribution from the rise in concomitant procedures enabled by the new DRG, which became effective in October. Impressive Value-Adding Acquisitions: Boston Scientific's recent acquisitions have added numerous products with immense potential. The company's recently completed strategic buyouts include Bolt Medical. Earlier, BSX had acquired Cortex, an advanced AF mapping solution. The company also acquired Silk Road to broaden in the field of vascular medicine. Boston Scientific also completed the acquisition of Axonics in the fourth quarter of 2024. Sales from closed acquisitions contributed 400 basis points in the first quarter, resulting in 18.2% organic revenue growth for Boston Scientific. The company is currently looking forward to close the acquisitions of SoniVie and Intera Oncology. Downside for BSX Stock Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters, as in the case of other important MedTech players. For 2025, the company expects a 50-basis point headwind from foreign exchange on revenues. BSX Stock's Estimate Trend The Zacks Consensus Estimate for 2025 earnings per share has remained unchanged at $2.91 in the past 30 days. The Zacks Consensus Estimate for 2025 revenues is pegged at $19.50 billion, indicating a 16.4% rise from the year-ago reported number. Other Key Picks Some other top-ranked stocks in the broader medical space are Align Technology ALGN, Abbott Laboratories ABT and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Abbott, currently carrying a Zacks Rank #2, has an earnings yield of 3.8% compared with the industry's 0.6%. Shares of the company have surged 129.7% compared with the industry's 35.9% gain. ABT's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.6%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report
Medscape
03-07-2025
- Health
- Medscape
Neuromodulation Effective for Migraine With and Without Aura
MINNEAPOLIS — Remote electrical neuromodulation (REN) appears to be a safe and effective option for a broad range of migraine types including migraine with or without aura and chronic migraine in patients who experience pain following treatment with onabotulinumtoxinA, two new studies suggested. Results of the first study, which included more than 31,000 individuals — most with migraine with or without aura — showed that use of an REN device provided relief from pain, functional disability, and nausea within 2 hours of treatment. The second study, which included 60 participants with chronic migraine receiving onabotulinumtoxinA treatment, showed that those using the REN device experienced significantly less pain during and after the procedure compared to those using a sham device. Patients often look for nonpharmacologic options to treat migraine, such as vitamins, herbs, and chiropractic care, among other options, study investigator Alan M. Rapoport, MD, clinical professor of neurology at the David Geffen School of Medicine at UCLA, told Medscape Medical News . 'We're always looking for something non-medicinal that patients would be willing to try. It's really good to have studies that show that this works as well as, or better than, any of those things.' The findings were presented at the American Headache Society (AHS) Annual Meeting 2025. Another Treatment Option Migraine with aura affects approximately 30% of patients, and research into whether it affects severity or response to treatment is limited, the researchers noted. Nerivio (Theranica; Bridgewater, New Jersey) is FDA-cleared for use in patients as young as 8 years old for the acute and preventive treatment of migraine, including chronic migraine, in adolescents and adults. In 2021, the AHS recommended REN therapy for patients who do not respond to first-line treatments such as triptans. Using prospective, real-world data, investigators evaluated 31,715 patients who used an REN device to treat 751,404 acute migraine attacks between January 2019 and September 2024. In both groups, patients had an average age of 37.5 years, and 86.5% were women. Researchers categorized 311,394 attacks in 9491 patients as migraine with aura, while 440,010 attacks in 22,224 patients had migraine without aura. Two key endpoints were assessed — the clinical characteristics of migraine with and without aura and the treatment efficacy of REN therapy in both groups. Patients used a smartphone app linked to the REN device to report pain intensity, functional disability, and migraine-associated symptoms during the attack and again 2 hours after its onset. When comparing migraine with and without aura, researchers classified patients as symptomatic if they reported moderate or severe pain and functional disability during at least half of the treatments. Similarly, if patients reported photophobia, phonophobia, and/or nausea with a migraine attack with either migraine type at least half the time, patients would be placed in a group for that specific symptom. The researchers also evaluated pain relief, pain freedom, functional disability relief, and functional disability freedom, which was measured by a consistent positive change in symptom status for at least half of treatments at 2 hours compared with prior treatment. Compared with patients who did not experience migraine with aura, those who did were significantly younger (36.2 vs 38.0 years) and reported higher rates of moderate to severe pain (91.1% vs 82.3%) and functional disability (68.9% vs 54.8%). They also had a greater prevalence of photophobia (80.6% vs 72.2%), phonophobia (67.2% vs 58.8%), and nausea or vomiting (45.9% vs 35.6%). Growing Evidence of Efficacy Findings from both studies add to growing evidence — including a randomized, double-blind, placebo-controlled trial — supporting the effectiveness of REN for migraine pain. Migraine with aura affects about 30% of patients, but its impact on symptom severity or treatment response remains underexplored. To address this, researchers analyzed prospective, real-world data from 31,715 patients who used an REN device to treat over 750,000 migraine attacks between January 2019 and September 2024. The average patient age was 37.5 years, and 86.5% were women. Among them, 311,394 attacks in 9491 patients were classified as migraine with aura, while 440,010 attacks in 22,224 patients were without aura. Two main endpoints were assessed: clinical characteristics of migraine with vs without aura and the efficacy of REN therapy in both groups. Patients reported pain intensity, functional disability, and associated symptoms via a smartphone app during the attack and again 2 hours later. Patients were classified as symptomatic if they reported moderate or severe pain and disability in at least half of treatments. Similarly, frequent photophobia, phonophobia, or nausea placed them in symptom-specific groups. Efficacy outcomes included pain relief, pain freedom, and improvement or resolution of functional disability, all measured by consistent symptom improvement in at least half of treatments at the 2-hour mark. Compared to those without aura, patients with aura were younger (36.2 vs 38.0 years) and had higher rates of moderate to severe pain (91.1% vs 82.3%), disability (68.9% vs 54.8%), photophobia (80.6% vs 72.2%), phonophobia (67.2% vs 58.8%), and nausea/vomiting (45.9% vs 35.6%). The majority in both groups experienced pain relief (69.8% vs 67.0%) and functional disability improvement (69.7% vs 62.1%) within 2 hours. Roughly one quarter achieved pain freedom (24.8% vs 26.7%), and about one third reported complete relief from functional disability (34.3% vs 35.6%). Dramatic Improvement Of all the outcomes evaluated, only functional disability relief at 2 hours was significantly greater in the migraine with aura group compared to those without aura ( P < .001). No significant between-group differences were found for the other pain-related outcomes. Both groups also experienced similar relief from migraine-associated symptoms at 2 hours, including photophobia (32.0% vs 28.5%), phonophobia (42.8% vs 38.9%), and nausea/vomiting (63.2% vs 55.1%). Relief from nausea/vomiting was significantly greater in the aura group ( P < .001), but there were no significant differences in photophobia or phonophobia relief between the groups. Regarding safety, only 0.33% of patients reported device-related adverse events, and no serious adverse events were observed. Rapoport noted that the key takeaway is this: Although migraine with aura tends to be more severe in some respects than migraine without aura, both types showed similarly strong and dramatic improvement with treatment. OnabotulinumtoxinA was the sole FDA-approved treatment for chronic migraine for many years, and patients have frequently reported pain and anxiety linked to its use as a treatment for chronic migraine, Nan Cheng, MD, assistant professor in the Department of Neurology at the University of California, Irvine School of Medicine, told conference attendees. The PREEMPT Trial The PREEMPT protocol clinicians use for treating chronic migraine with onabotulinumtoxinA can range from 31 to 40 injections per session, she noted. 'That can really cause a lot of pain and a lot of anxiety for patients,' Cheng said, noting that there are no 'established strategies to reduce procedural pain or to reduce postinjection headache' associated with onabotulinumtoxinA treatment. For the study, Cheng and colleagues evaluated 60 patients receiving onabotulinumtoxinA treatment for chronic migraine at a single center. Participants had a mean age of 48 years; most were women (81.7%) and averaged 14.7 headache days per month. Nearly half (48.3%) had migraine with or without aura, while 46.6% reported migraine with aura only. Participants wore either an REN or sham device starting 10 minutes before treatment and removed it afterward. Pain was rated at the start, midpoint, and end of the procedure using a 0-100 visual analog scale. Follow-up calls the next day assessed postprocedure headaches and adverse events. Device use alternated between REN and sham at each treatment visit. 'In the first visit, they would undergo some baseline screening and have their Botox as per usual. In the second phase, they were randomized to either the active device or the sham device while receiving Botox. 'In phase 3, then they crossed over to the other side of their active or sham device with their Botox, so if a patient was on the active device for phase two, they would then be on the sham device for phase three,' Cheng said. REN therapy significantly reduced intraprocedure pain by 14.8 points and postprocedure pain by 18.8 points compared to the sham device ( P < .001 for both). Patients using the active device were also significantly less likely to develop postprocedure headaches (15.4% vs 54.7%) compared with a baseline rate of 39% (odds ratio, 0.28; P = .008). The study was stopped early after meeting prespecified criteria for effectiveness. Cheng noted that REN therapy proved to be safe, feasible, and effective, with a true analgesic effect beyond placebo and easy integration into clinical practice. Sham Comparison Needed Commenting on the research for Medscape Medical News , Kevin Weber, MD, MHA, assistant professor of neurology and director of the Division of Headache at The Ohio State University Neurological Institute, Columbus, Ohio, said collectively, the studies show that REN therapy can be safe, but more research is needed. 'These studies indicate that this device can be a safe treatment for migraine and also could potentially used for mitigation of Botox procedural pain,' said Weber, who was not involved in the research. However, there is a lower bar to clear for FDA granting device approvals and clearance compared to when the agency approves a pharmaceutical drug, Weber, who is also associate fellowship director of the United Council for Neurologic Subspecialties headache fellowship, added. The large sample size in the study of patients with migraine with and without aura supports broader generalizability of the findings, though it lacked a sham control. Similarly, the chronic migraine study did not assess whether participants could identify whether they received the active or sham REN device, Weber noted. He emphasized the need for further research, including larger studies incorporating both sham devices and sham testing. The study of REN therapy in chronic migraine patients receiving onabotulinumtoxinA did not assess whether participants could distinguish between the active and sham devices, Weber noted. He emphasized the need for larger studies that include both sham devices and sham controls. 'If the sham is good and a true placebo, patients guessing which treatment they received shouldn't be better than chance,' he said.
